HEADER ISOMERASE/IMMUNOSUPPRESSANT 14-JAN-07 2OJU TITLE X-RAY STRUCTURE OF COMPLEX OF HUMAN CYCLOPHILIN J WITH CYCLOSPORIN A COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEPTIDYL-PROLYL CIS-TRANS ISOMERASE-LIKE 3; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: PPIASE, ROTAMASE, CYCLOPHILIN-LIKE PROTEIN PPIL3, COMPND 5 CYCLOPHILIN J, CYPJ; COMPND 6 EC: 5.2.1.8; COMPND 7 ENGINEERED: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLOSPORIN A; COMPND 10 CHAIN: C, D; COMPND 11 SYNONYM: CICLOSPORIN, CICLOSPORINE; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 TISSUE: FETAL BRAIN; SOURCE 6 GENE: PPIL3B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 9 EXPRESSION_SYSTEM_STRAIN: ER2566; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PTXB1; SOURCE 12 MOL_ID: 2; SOURCE 13 SYNTHETIC: YES; SOURCE 14 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM INFLATUM; SOURCE 15 ORGANISM_TAXID: 29910 KEYWDS ISOMERASE-IMMUNOSUPPRESSANT COMPLEX, CYCLOPHILIN-CYCLOSPORIN COMPLEX, KEYWDS 2 CYCLOSPORIN A, IMMUNOSUPPRESSANT, CYCLOPHILIN EXPDTA X-RAY DIFFRACTION AUTHOR Z.XIA,L.HUANG REVDAT 6 15-NOV-23 2OJU 1 LINK REVDAT 5 25-OCT-23 2OJU 1 SEQADV LINK REVDAT 4 27-JUL-11 2OJU 1 REMARK REVDAT 3 13-JUL-11 2OJU 1 VERSN REVDAT 2 24-FEB-09 2OJU 1 VERSN REVDAT 1 22-JAN-08 2OJU 0 JRNL AUTH J.CHEN,S.CHEN,L.HUANG,X.ZHAO,J.TAN,C.HUANG,H.SAIYIN,M.ZHANG, JRNL AUTH 2 X.ZENG,J.XI,B.WAN,Y.ZHAO,Z.XIA,H.JIANG,Q.YI,J.O.LIU,L.YU JRNL TITL TARGETING CYCLOPHILIN J, A NOVEL PEPTIDYL-PROLYL ISOMERASE, JRNL TITL 2 CAN INDUCE CELLULAR G1/S ARREST AND REPRESS THE GROWTH OF JRNL TITL 3 HEPATOCELLULAR CARCINOMA JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 220039.630 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 93.7 REMARK 3 NUMBER OF REFLECTIONS : 18460 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.237 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.700 REMARK 3 FREE R VALUE TEST SET COUNT : 1793 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.40 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.49 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 72.60 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1264 REMARK 3 BIN R VALUE (WORKING SET) : 0.3590 REMARK 3 BIN FREE R VALUE : 0.4290 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 9.60 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 135 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.037 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2762 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 32 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 42.50 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 51.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.47000 REMARK 3 B22 (A**2) : -2.47000 REMARK 3 B33 (A**2) : 4.95000 REMARK 3 B12 (A**2) : 1.34000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM SIGMAA (A) : 0.43 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.39 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.52 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.90 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.770 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.400 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.330 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.100 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.230 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.28 REMARK 3 BSOL : 33.27 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 2 : ION.PARAM REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : WATER.TOP REMARK 3 TOPOLOGY FILE 2 : ION.TOP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OJU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 23-JAN-07. REMARK 100 THE DEPOSITION ID IS D_1000041225. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-FEB-05 REMARK 200 TEMPERATURE (KELVIN) : 293.0 REMARK 200 PH : 7.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : BSRF REMARK 200 BEAMLINE : 3W1A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9826 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19272 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.6 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.07600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.49 REMARK 200 COMPLETENESS FOR SHELL (%) : 83.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.40600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 2OK3 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.63 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.04 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1MOL/L TRIS-HCL(PH=7.4), 6%(V/V) REMARK 280 DMSO, 18%(W/V) PEG8000, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 293.0K, PH 7.4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 66.98100 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 133.96200 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 133.96200 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 66.98100 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1030 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8710 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1040 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8610 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -6.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 THE CYCLOSPORIN A IS CYCLIC PEPTIDE, A MEMBER OF IMMUNOSUPPRESSANT REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION REMARK 400 IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 1 REMARK 465 ARG A 2 REMARK 465 ALA A 166 REMARK 465 GLN A 167 REMARK 465 GLN B 167 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 14 -15.59 -49.93 REMARK 500 PHE A 55 -82.44 -108.18 REMARK 500 PHE B 23 73.17 -69.94 REMARK 500 THR B 27 76.80 -115.90 REMARK 500 PHE B 55 -85.20 -105.47 REMARK 500 LYS B 139 39.71 -80.86 REMARK 500 ASN B 143 -130.97 -61.90 REMARK 500 GLU B 144 -30.19 -158.08 REMARK 500 ABA D 6 76.79 -119.13 REMARK 500 REMARK 500 REMARK: NULL REMARK 650 REMARK 650 HELIX REMARK 650 DETERMINATION METHOD: AUTHOR DETERMINED REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN C OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN D OF CYCLOSPORIN A REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BCK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 C REMARK 900 RELATED ID: 1C5F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CSA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1CWA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 1CWB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 1CWC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 D REMARK 900 RELATED ID: 1CWH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A MODIFIED AT POSITION 7 REMARK 900 RELATED ID: 1CWI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITION 7 REMARK 900 RELATED ID: 1CWJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED REMARK 900 CYCLOSPORIN C AT POSITIONS 1, AND 9 REMARK 900 RELATED ID: 1CYA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYB RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 1 REMARK 900 RELATED ID: 1M63 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX REMARK 900 RELATED ID: 1MF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN REMARK 900 CYCLOPHILIN AND CYCLOSPORIN A REMARK 900 RELATED ID: 1MIK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 6 REMARK 900 RELATED ID: 1QNG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1QNH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE REMARK 900 MUTANT) COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1XQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2ESL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2POY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2RMA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 2RMC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2WFJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2X2C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2X7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2Z6W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3BO7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII REMARK 900 COMPLEXED WIT CYCLOSPORIN A REMARK 900 RELATED ID: 3CYS RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3EOV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE N-TERMINAL 6 RESIDUES 'SRVDGG' IN CHAINS A AND B IS REMARK 999 AN ENGINEERED EXPRESSION TAG DBREF 2OJU A 7 167 UNP Q9H2H8 PPIL3_HUMAN 1 161 DBREF 2OJU B 7 167 UNP Q9H2H8 PPIL3_HUMAN 1 161 DBREF 2OJU C 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2OJU D 1 11 NOR NOR00033 NOR00033 1 11 SEQADV 2OJU SER A 1 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU ARG A 2 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU VAL A 3 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU ASP A 4 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU GLY A 5 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU GLY A 6 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU SER B 1 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU ARG B 2 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU VAL B 3 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU ASP B 4 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU GLY B 5 UNP Q9H2H8 EXPRESSION TAG SEQADV 2OJU GLY B 6 UNP Q9H2H8 EXPRESSION TAG SEQRES 1 A 167 SER ARG VAL ASP GLY GLY MET SER VAL THR LEU HIS THR SEQRES 2 A 167 ASP VAL GLY ASP ILE LYS ILE GLU VAL PHE CYS GLU ARG SEQRES 3 A 167 THR PRO LYS THR CYS GLU ASN PHE LEU ALA LEU CYS ALA SEQRES 4 A 167 SER ASN TYR TYR ASN GLY CYS ILE PHE HIS ARG ASN ILE SEQRES 5 A 167 LYS GLY PHE MET VAL GLN THR GLY ASP PRO THR GLY THR SEQRES 6 A 167 GLY ARG GLY GLY ASN SER ILE TRP GLY LYS LYS PHE GLU SEQRES 7 A 167 ASP GLU TYR SER GLU TYR LEU LYS HIS ASN VAL ARG GLY SEQRES 8 A 167 VAL VAL SER MET ALA ASN ASN GLY PRO ASN THR ASN GLY SEQRES 9 A 167 SER GLN PHE PHE ILE THR TYR GLY LYS GLN PRO HIS LEU SEQRES 10 A 167 ASP MET LYS TYR THR VAL PHE GLY LYS VAL ILE ASP GLY SEQRES 11 A 167 LEU GLU THR LEU ASP GLU LEU GLU LYS LEU PRO VAL ASN SEQRES 12 A 167 GLU LYS THR TYR ARG PRO LEU ASN ASP VAL HIS ILE LYS SEQRES 13 A 167 ASP ILE THR ILE HIS ALA ASN PRO PHE ALA GLN SEQRES 1 B 167 SER ARG VAL ASP GLY GLY MET SER VAL THR LEU HIS THR SEQRES 2 B 167 ASP VAL GLY ASP ILE LYS ILE GLU VAL PHE CYS GLU ARG SEQRES 3 B 167 THR PRO LYS THR CYS GLU ASN PHE LEU ALA LEU CYS ALA SEQRES 4 B 167 SER ASN TYR TYR ASN GLY CYS ILE PHE HIS ARG ASN ILE SEQRES 5 B 167 LYS GLY PHE MET VAL GLN THR GLY ASP PRO THR GLY THR SEQRES 6 B 167 GLY ARG GLY GLY ASN SER ILE TRP GLY LYS LYS PHE GLU SEQRES 7 B 167 ASP GLU TYR SER GLU TYR LEU LYS HIS ASN VAL ARG GLY SEQRES 8 B 167 VAL VAL SER MET ALA ASN ASN GLY PRO ASN THR ASN GLY SEQRES 9 B 167 SER GLN PHE PHE ILE THR TYR GLY LYS GLN PRO HIS LEU SEQRES 10 B 167 ASP MET LYS TYR THR VAL PHE GLY LYS VAL ILE ASP GLY SEQRES 11 B 167 LEU GLU THR LEU ASP GLU LEU GLU LYS LEU PRO VAL ASN SEQRES 12 B 167 GLU LYS THR TYR ARG PRO LEU ASN ASP VAL HIS ILE LYS SEQRES 13 B 167 ASP ILE THR ILE HIS ALA ASN PRO PHE ALA GLN SEQRES 1 C 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 D 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA HET DAL C 1 5 HET MLE C 2 9 HET MLE C 3 9 HET MVA C 4 8 HET BMT C 5 13 HET ABA C 6 6 HET SAR C 7 5 HET MLE C 8 9 HET MLE C 10 9 HET DAL D 1 5 HET MLE D 2 9 HET MLE D 3 9 HET MVA D 4 8 HET BMT D 5 13 HET ABA D 6 6 HET SAR D 7 5 HET MLE D 8 9 HET MLE D 10 9 HETNAM DAL D-ALANINE HETNAM MLE N-METHYLLEUCINE HETNAM MVA N-METHYLVALINE HETNAM BMT 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SAR SARCOSINE FORMUL 3 DAL 2(C3 H7 N O2) FORMUL 3 MLE 8(C7 H15 N O2) FORMUL 3 MVA 2(C6 H13 N O2) FORMUL 3 BMT 2(C10 H19 N O3) FORMUL 3 ABA 2(C4 H9 N O2) FORMUL 3 SAR 2(C3 H7 N O2) FORMUL 5 HOH *32(H2 O) HELIX 1 1 THR A 27 SER A 40 1 14 HELIX 2 2 GLN A 114 ASP A 118 5 5 HELIX 3 3 GLY A 130 LYS A 139 1 10 HELIX 4 4 THR B 27 SER B 40 1 14 HELIX 5 5 GLN B 114 ASP B 118 5 5 HELIX 6 6 GLY B 130 LYS B 139 1 10 SHEET 1 AA 8 ARG A 50 ILE A 52 0 SHEET 2 AA 8 MET A 56 THR A 59 -1 O MET A 56 N ILE A 52 SHEET 3 AA 8 PHE A 107 THR A 110 -1 O PHE A 107 N THR A 59 SHEET 4 AA 8 VAL A 92 MET A 95 -1 O VAL A 92 N THR A 110 SHEET 5 AA 8 VAL A 123 ASP A 129 -1 N PHE A 124 O VAL A 93 SHEET 6 AA 8 GLY A 16 VAL A 22 -1 O LYS A 19 N ILE A 128 SHEET 7 AA 8 SER A 8 THR A 13 -1 O VAL A 9 N ILE A 20 SHEET 8 AA 8 ILE A 155 HIS A 161 -1 N LYS A 156 O HIS A 12 SHEET 1 BA 9 CYS B 46 ILE B 47 0 SHEET 2 BA 9 HIS B 154 HIS B 161 -1 N ILE B 155 O CYS B 46 SHEET 3 BA 9 SER B 8 THR B 13 -1 O SER B 8 N HIS B 161 SHEET 4 BA 9 GLY B 16 VAL B 22 -1 O GLY B 16 N THR B 13 SHEET 5 BA 9 VAL B 123 ASP B 129 -1 O LYS B 126 N GLU B 21 SHEET 6 BA 9 VAL B 92 MET B 95 -1 O VAL B 93 N PHE B 124 SHEET 7 BA 9 PHE B 107 THR B 110 -1 O PHE B 108 N SER B 94 SHEET 8 BA 9 MET B 56 THR B 59 -1 O VAL B 57 N ILE B 109 SHEET 9 BA 9 ARG B 50 ILE B 52 -1 O ARG B 50 N GLN B 58 SSBOND 1 CYS A 24 CYS A 31 1555 1555 2.02 SSBOND 2 CYS B 24 CYS B 31 1555 1555 2.02 LINK C DAL C 1 N MLE C 2 1555 1555 1.34 LINK N DAL C 1 C ALA C 11 1555 1555 1.33 LINK C MLE C 2 N MLE C 3 1555 1555 1.34 LINK C MLE C 3 N MVA C 4 1555 1555 1.34 LINK C MVA C 4 N BMT C 5 1555 1555 1.34 LINK C BMT C 5 N ABA C 6 1555 1555 1.33 LINK C ABA C 6 N SAR C 7 1555 1555 1.35 LINK C SAR C 7 N MLE C 8 1555 1555 1.35 LINK C MLE C 8 N VAL C 9 1555 1555 1.33 LINK C VAL C 9 N MLE C 10 1555 1555 1.34 LINK C MLE C 10 N ALA C 11 1555 1555 1.33 LINK C DAL D 1 N MLE D 2 1555 1555 1.35 LINK N DAL D 1 C ALA D 11 1555 1555 1.33 LINK C MLE D 2 N MLE D 3 1555 1555 1.34 LINK C MLE D 3 N MVA D 4 1555 1555 1.34 LINK C MVA D 4 N BMT D 5 1555 1555 1.35 LINK C BMT D 5 N ABA D 6 1555 1555 1.33 LINK C ABA D 6 N SAR D 7 1555 1555 1.34 LINK C SAR D 7 N MLE D 8 1555 1555 1.35 LINK C MLE D 8 N VAL D 9 1555 1555 1.33 LINK C VAL D 9 N MLE D 10 1555 1555 1.35 LINK C MLE D 10 N ALA D 11 1555 1555 1.33 SITE 1 AC1 19 GLU A 32 ALA A 36 ALA A 39 ARG A 50 SITE 2 AC1 19 PHE A 55 GLN A 58 GLY A 66 ALA A 96 SITE 3 AC1 19 ASN A 97 ASN A 98 GLN A 106 PHE A 108 SITE 4 AC1 19 HIS A 116 TYR A 121 PRO A 164 HOH A2003 SITE 5 AC1 19 SER B 1 VAL B 3 HOH C2001 SITE 1 AC2 17 LEU B 35 ALA B 36 ALA B 39 SER B 40 SITE 2 AC2 17 ARG B 50 PHE B 55 GLN B 58 GLY B 66 SITE 3 AC2 17 ARG B 67 ALA B 96 ASN B 97 ASN B 98 SITE 4 AC2 17 GLN B 106 PHE B 108 HIS B 116 TYR B 121 SITE 5 AC2 17 HOH B2004 CRYST1 64.387 64.387 200.943 90.00 90.00 120.00 P 31 2 1 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015531 0.008967 0.000000 0.00000 SCALE2 0.000000 0.017934 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004977 0.00000